Amneal (AMRX) Q2 EPS Jumps 56%

Amneal Pharmaceuticals (NASDAQ:AMRX), a developer and manufacturer of specialty and generic pharmaceuticals, released its second quarter earnings on August 5, 2025. The company reported stronger-than-expected profitability, as non-GAAP EPS of $0.25 exceeded analyst estimates, with adjusted diluted earnings per share at $0.25 (non-GAAP), topping analyst non-GAAP EPS estimates of $0.17. However, net revenue (GAAP) reached $725 million, missing GAAP revenue expectations by $19.56125 million. The standout performance came from its specialty segment, particularly thanks to new branded products, a step-up in research and development spending, and a modest year-over-year growth in GAAP sales, though top-line revenue (GAAP) came in lower than anticipated. Source: Analyst estimates for the quarter provided by FactSet. Amneal Pharmaceuticals is a U.S.-based pharmaceutical manufacturer known for its broad portfolio of generics, injectable medicines, biosimilars, and specialty branded therapies. Its business relies on a mix of affordable medications and highly specialized treatments for diseases with unmet medical needs. The company’s headquarters is in Bridgewater, New Jersey, with manufacturing and R&D facilities internationally, including key sites in the U.S. India, and Ireland.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool